Vall d'Hebron University Hospital at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

Vall d'Hebron University Hospital brings 3 presentations to ISLB 2026 in Madrid. Its work centres on making circulating tumour DNA part of routine treatment decisions in solid tumours. One study compares commercial PCR assays for plasma ESR1 testing across Spain, and another makes the case for blood tumour DNA to catch resistance mutations that tissue testing misses.

OrganizationISLB 2026 Attendance
vallhebron.com
Hospitals & cancer centres
Public university hospital in Barcelona, Spain, whose campus includes the Vall d'Hebron Institute of Oncology.
Industry
Sat Nov 7
12:30pm–1:30pm
Industry
Sat Nov 7
12:30pm–1:30pm
Part of Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors
Bringing ctDNA into Routine Care: Lessons from mCRPC
Industry hosted by MSD
Clinical use · ctDNA & MRD
Poster
Part of Poster sessions
Harmonizing Plasma ESR1 Testing Across Spain: Results from the First Nationwide Multicenter Comparison of Commercial PCR Assays
Pre-analytics
Collaborators: Hospital del Mar

Explore the full ISLB 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ISLB 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Vall d'Hebron University Hospital

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the International Society of Liquid Biopsy (ISLB). Submit a correction